Building on the potential of targeting EGFR, Cetuximab-IRDye800 (UAB Vector Production Facility, University of Alabama, Birmingham, AB, USA)—a fluorescently labeled monoclonal antibody—has demonstrated its ability to provide highly specific contrast in both subcutaneous and orthotopic glioblastoma mouse models [20]. The gene discussed is EGFR; the disease is glioblastoma.